CIK 0001636282
- Large accelerated filer
Spyre Therapeutics, Inc.
Sign in to watch- Ticker
- SYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464312787
- Phone
- +1 617-651-5940
- Business address
- 221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aeglea BioTherapeutics, Inc.
- 4 Planned sale Chief Executive Officer sold 15,000 shares at an average $29.02 ($435,356)
- 4 Planned sale Chief Executive Officer sold 45,000 shares at an average $23.33 ($1,049,778)
- 4 Open-market sale Chief Financial Officer sold 18,428 shares at $16.26 ($299,639)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Other acquisition Director acquired 105,379 shares (other)
- 4 Planned sale Director sold 6,700 shares at $36.76 ($246,313)
- 4 Planned sale Director sold 300 shares at $36.43 ($10,929)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Financial Officer sold 18,531 shares at $28.17 ($522,074)
- 4 Derivatives Options or other derivatives
Page 3 of 14 · 271 filings